Our study showed that people with poor function of ABCG2 had higher risk of myositis when taking atorvastatin (P  =  3.58×10-3, OR = 2.27, 95% CI = 1.31–3.94) or simvastatin (P  =  1.26×10-2, OR = 3.43, 95% CI = 1.3–9.05); whereas people with ABCG2 decreased function phenotype had higher risk of myalgia while taking fluvastatin (P  =  5.39×10-3, OR = 1.97, 95% CI = 1.22–3.18) (Fig. 5a–c and Supplementary Table 9). Here, ABCG2 is linked to myositis disease.